New Study Results Further Reinforce that the Corus® CAD Test Helps Primary Care Clinicians Make Effective Referral Decisions for Patients with Suspected Obstructive Coronary Artery Disease
- Patients with a Low Corus CAD Score had 94% Reduced Odds of Referral to a Cardiologist -
- REGISTRY I Study Results Add to the Established Evidence Base Supporting the Clinical Utility of the Corus CAD Gene Expression Test in Real-World Clinical Practice -
PALO ALTO, Calif. – [May 05, 2014] - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the REGISTRY I study, which examined the assessment of non-acute chest pain and related symptoms that may be suggestive of obstructive coronary artery disease (CAD) in the primary care setting with the Corus® CAD blood-based gene expression test. The study, published online in the American Journal of Medical Quality in May 2014, found a strong association between cardiac referral rates by low (≤15) and elevated (>15) Corus CAD score groups, with only 6% (10/167) of the low Corus CAD score patients versus 70% (122/175) of the elevated Corus CAD score patients being referred for further cardiac evaluation (P < .0001). Corus CAD is the first and only commercially available blood-based gene expression test that provides a current-state assessment of obstructive CAD in non-diabetic patients presenting with typical or atypical symptoms. With a 96% negative predictive value and 89% sensitivity, Corus CAD can help clinicians accurately rule out obstructive CAD as the source of their patients’ symptoms, so that they may investigate other non-cardiac causes.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.